Mohammedi Savliwala, MD
Allergy & Immunology · Bloomfield Hills, MINPI 1992862817
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 1,005 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,005 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Alk-abello, Inc$3K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$2K
- CSL Behring$1K
- plus $9K from 38 others
What the payments were for
- Consulting fees$1,7037%
- Speaking & faculty fees$1751%
- Food & beverage$22,00990%
- Education$4532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,340 in reported general payments places this provider in the 85th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 139 | $594,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 272 | $209,601 |
| Dupixent SyringeDupilumab | 57 | $208,480 |
| XolairOmalizumab | 59 | $189,543 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $171,255 |
| TezspireTezepelumab-Ekko | 39 | $165,708 |
| Fasenra PenBenralizumab | 17 | $92,645 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $86,766 |
| Spiriva RespimatTiotropium Bromide | 29 | $24,031 |
| Epinephrine | 84 | $21,947 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $20,431 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $19,198 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $18,501 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,586 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $16,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,876 | $242,390335 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Pulmicort Flexhaler | $5,605 | $216,932147 claims |
| CSL BehringHizentra | $1,276 | $171,25536 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $983 | $86,76613 claims |
| Boehringer IngelheimSpiriva Respimat | $409 | $24,03129 claims |
| Hikma Pharmaceuticals USAEpinephrine | $57 | $21,94784 claims |
| MerckDulera | $22 | $7,76219 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $131 | $4,89414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Bloomfield Hills
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
- Jason ParisLivonia$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.